References
1. Bandaru S, Marri VK, Akka J, Alvala M, Mundluru HP. Association of transforming growth factor-Beta 1 promoter variant -509 c/t with bronchial asthma in South Indian population. Inflammation. 2015;38(1):409-14.
2. Masoli M, Fabian D, Holt S, Beasley RJA. The global burden of asthma: executive summary of the GINA Dissemination Committee Report. Allergy. 2004;59(5):469-78.
3. De Paiva AC, Marson FA, Ribeiro JD, Bertuzzo CS. Asthma: Gln27Glu and Arg16Gly polymorphisms of the beta2-adrenergic receptor gene as risk factors. Allergy Asthma Clin Immunol. 2014;10(1):8-.
4. National Asthma Education Prevention Program. Expert Panel Report 3 (EPR-3): Guidelines for the diagnosis and management of asthma-summary report 2007. The Journal of allergy and clinical immunology. 2007;120(5 Suppl):S94-S138.
5. Drazen JM, Silverman EK, Lee TJBMB. Heterogeneity of therapeutic responses in asthma. British Medical Bulletin. 2000;56(4):1054-70.
6. Donohue JF. Therapeutic responses in asthma and COPD: Bronchodilators. CHEST Journal. 2004;126(2):125-37.
7. Silverman EK, Kwiatkowski DJ, Sylvia JS, Lazarus R, Drazen JM, Lange C, et al. Family-based association analysis of beta2-adrenergic receptor polymorphisms in the childhood asthma management program. The Journal of allergy and clinical immunology. 2003;112(5):870-6.
8. Johnson M. The beta-adrenoceptor. American journal of respiratory and critical care medicine. 1998;158(5 Pt 3):S146-S53.
9. Liggett SB. The pharmacogenetics of β2-adrenergic receptors: Relevance to asthma. Allergy Clin Immunol. 2000;105(2):487-92.
10. Weiss ST, Litonjua AA, Lange C, Lazarus R, Liggett SB, Bleecker ER, et al. Overview of the pharmacogenetics of asthma treatment. Pharmacogenomics. 2006;6(5):311-26.
11. Adeloye D, Chan KY, Rudan I, Campbell HJCMJ. An estimate of asthma prevalence in Africa: a systematic analysis. Croat Med J Dec. 2013;54(6):519-31.
12. Reihsaus E, Innis M, MacIntyre N, Liggett SB. Mutations in the gene encoding for the beta 2-adrenergic receptor in normal and asthmatic subjects. American journal of respiratory cell and molecular biology. 1993;8(3):334-9.
13. Mohamedhussein A, Sayed SS, Eldien HMS, Assar AM, Yehia FEJL. Beta 2 adrenergic receptor genetic polymorphisms in bronchial asthma: Relationship to disease risk, severity, and treatment response. Lung. 2018;196(6):673-80.
14. Sahi PK, Shastri S, Lodha R, Gupta N, Pandey RM, Kabra SK, et al. ADRB2 polymorphism and salbutamol responsiveness in northern indian children with mild to moderate exacerbation of asthma. Indian Pediatr. 2016;53(3):211-5.
15. Bandaru S, Akka J, Marri VK, Alvala M, Ponnala D, Mundluru HPJI. Analysis of ADRB2 (Arg16Gly) gene variant with susceptibility, pharmacogenetic response and disease severity in South Indian asthmatics. Inflammation. 2015;38(6):2146-55.
16. Shah NJ, Vinod Kumar S, Gurusamy U, Annan Sudarsan AKA, Shewade DGJJoAR. Effect of ADRB2 (adrenergic receptor β2) gene polymorphisms on the occurrence of asthma and on the response to nebulized salbutamol in South Indian patients with bronchial asthma. Asthma. 2015;52(8):755-62.
17. Tellería JJ, Blanco-Quirós A, Muntión S, Garrote JA, Castro JJRM. Tachyphylaxis to β 2-agonists in Spanish asthmatic patients could be modulated by β 2-adrenoceptor gene polymorphisms. Respir Med. 2006;100(6):1072-8.
18. Kukreti R, Bhatnagar P, B-Rao C, Gupta S, Madan B, Das C, et al. Beta(2)-adrenergic receptor polymorphisms and response to salbutamol among Indian asthmatics*. Pharmacogenomics. 2005;6(4):399-410.
19. Fu J, Chen H, Hu L, Zhang H, Ma Y, Chen Y. Association between the genetic polymorphisms of beta2-adrenergic receptor gene and the asthma susceptibility and clinical phenotypes in a Chinese population. Chinese journal of medical genetics. 2002;19(1):41-5.
20. Martinez FD, Graves PE, Baldini M, Solomon S, Erickson RPJJoCI. Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing. Clin Invest. 1997;100(12):3184-8.
21. Moher D, Liberati A, Tetzlaff J, Altman DGJIJoS. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Surg. 2010;8(5):336-41.
22. Sohani ZN, Meyre D, De Souza RJ, Joseph P, Gandhi M, Dennis BB, et al. Assessing the quality of published genetic association studies in meta-analyses: the quality of genetic studies (Q-Genie) tool. BMC Genet. 2015;16(1):50-.
23. Agonia I, Couras J, Cunha A, Andrade AJ, Macedo JP, Sousapinto BJC. IL-17, IL-21 and IL-22 polymorphisms in rheumatoid arthritis: A systematic review and meta-analysis. Cytokine. 2020;125:154813.
24. Galbraith RF. A Note on Graphical Presentation of Estimated Odds Ratios from Several Clinical-Trials. Statistics in Medicine. 1988 Aug;7(8):889-94.
25. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ (Clinical research ed). 1997;315(7109):629-34.
26. Sanchezmartin A, Garciasanchez A, Isidorogarcia MJMoMB. Review on pharmacogenetics and pharmacogenomics applied to the study of asthma. Methods Mol Biol. 2016;1434:255-72.
27. Pignatti Pf. Trends in pharmacogenomics of drugs used in the treatment of asthma. Pharmacol Res. 2004;49(4):343-9.
28. Litonjua AA, Gong L, Duan QL, Shin J, Moore MJ, Weiss ST, et al. Very important pharmacogene summary ADRB2. Pharmacogenet Genomics. 2010;20(1):64-9.
29. Hawkins GA, Peters SPJMoMB. Pharmacogenetics of Asthma. Methods Mol Biol. 2008;448:359-78.
30. Kersten ET, Koppelman GH. Pharmacogenetics of asthma: toward precision medicine. Curr Opin Pulm Med. 2017;23(1):12-20.
31. Nisar M, Walshaw M, Earis JE, Pearson MG, Calverley PMAJT. Assessment of reversibility of airway obstruction in patients with chronic obstructive airways disease. Thorax. 1990;45(3):190-4.
32. Kobilka BK, Dixon RA, Frielle T, Dohlman HG, Bolanowski MA, Sigal IS, et al. cDNA for the human beta 2-adrenergic receptor: a protein with multiple membrane-spanning domains and encoded by a gene whose chromosomal location is shared with that of the receptor for platelet-derived growth factor. Proc Natl Acad Sci USA. 1987;84(1):46-50.
33. Moore WC, Meyers DA, Wenzel SE, Teague WG, Li H, Li X, et al. Identification of Asthma Phenotypes Using Cluster Analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med; 2010. p. 315-23.
34. Miranda C, Busacker A, Balzar S, John. Distinguishing severe asthmphenotypes: Role of age at onset and eosinophilic inflammation. Allergy Clin Immunol. 2004;113(1):101-8.
35. Maxwell TJ, Ameyaw M, Pritchard SC, Thornton N, Folayan G, Githanga J, et al. Beta-2 adrenergic receptor genotypes and haplotypes in different ethnic groups. Int J Mol Med. 2005;16(4):573-80.
36. Finkelstein Y, Bournissen FG, Hutson JR, Shannon MJJoA. Polymorphism of the ADRB2 gene and response to inhaled beta- agonists in children with asthma: a meta-analysis. Asthma. 2009;46(9):900-5.
37. Green S, Cole G, Jacinto M, Innis M, Liggett SBJJoBC. A polymorphism of the human beta 2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor. Journal of Biological Chemistry. 1993;268(31):23116-21.
38. Ortega VE, Hawkins GA, Moore WC, Hastie AT, Ampleford EJ, Busse WW, et al. Effect of rare variants in ADRB2 on risk of severe exacerbations and symptom control during longacting β agonist treatment in a multiethnic asthma population: a genetic study. Lancet Respir Med. 2014;2(3):204-13.
Table 1. Summary of articles included in this meta-analysis.